Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1989 May;27(5):620–625. doi: 10.1111/j.1365-2125.1989.tb03426.x

Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark.

A Drøhse 1, L Bathum 1, K Brøsen 1, L F Gram 1
PMCID: PMC1379929  PMID: 2757884

Abstract

The oxidation of mephenytoin was polymorphic in 358 healthy Danish volunteers. The ratio between the chromatographic peak areas of (S)- and (R)-mephenytoin (S/R) in 12 h urine was less than or equal to 0.48 in 349 extensive metabolizers (EM) and greater than or equal to 1 in 9 (2.5%) poor metabolizers (PM). Concomitant intake of mephenytoin and sparteine and subsequent assay by gas chromatography had no influence on the test results (mephenytoin S/R ratio or sparteine metabolic ratio). Among ten parents and seven siblings to six unrelated PM of mephenytoin only one (1/17 = 5.9%) was a PM. The pedigrees were compatible with an autosomal recessive mode of inheritance.

Full text

PDF
620

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brøsen K., Otton S. V., Gram L. F. Sparteine oxidation polymorphism in Denmark. Acta Pharmacol Toxicol (Copenh) 1985 Nov;57(5):357–360. doi: 10.1111/j.1600-0773.1985.tb00058.x. [DOI] [PubMed] [Google Scholar]
  2. Clark D. W. Genetically determined variability in acetylation and oxidation. Therapeutic implications. Drugs. 1985 Apr;29(4):342–375. doi: 10.2165/00003495-198529040-00003. [DOI] [PubMed] [Google Scholar]
  3. Eichelbaum M., Spannbrucker N., Steincke B., Dengler H. J. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol. 1979 Sep;16(3):183–187. doi: 10.1007/BF00562059. [DOI] [PubMed] [Google Scholar]
  4. Evans D. A., Mahgoub A., Sloan T. P., Idle J. R., Smith R. L. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet. 1980 Apr;17(2):102–105. doi: 10.1136/jmg.17.2.102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Gonzalez F. J., Skoda R. C., Kimura S., Umeno M., Zanger U. M., Nebert D. W., Gelboin H. V., Hardwick J. P., Meyer U. A. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature. 1988 Feb 4;331(6155):442–446. doi: 10.1038/331442a0. [DOI] [PubMed] [Google Scholar]
  6. Inaba T., Jurima M., Kalow W. Family studies of mephenytoin hydroxylation deficiency. Am J Hum Genet. 1986 May;38(5):768–772. [PMC free article] [PubMed] [Google Scholar]
  7. Inaba T., Jurima M., Nakano M., Kalow W. Mephenytoin and sparteine pharmacogenetics in Canadian Caucasians. Clin Pharmacol Ther. 1984 Nov;36(5):670–676. doi: 10.1038/clpt.1984.238. [DOI] [PubMed] [Google Scholar]
  8. Jurima M., Inaba T., Kadar D., Kalow W. Genetic polymorphism of mephenytoin p(4')-hydroxylation: difference between Orientals and Caucasians. Br J Clin Pharmacol. 1985 Apr;19(4):483–487. doi: 10.1111/j.1365-2125.1985.tb02673.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Küpfer A., Branch R. A. Stereoselective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation. Clin Pharmacol Ther. 1985 Oct;38(4):414–418. doi: 10.1038/clpt.1985.196. [DOI] [PubMed] [Google Scholar]
  10. Küpfer A., Desmond P., Patwardhan R., Schenker S., Branch R. A. Mephenytoin hydroxylation deficiency: kinetics after repeated doses. Clin Pharmacol Ther. 1984 Jan;35(1):33–39. doi: 10.1038/clpt.1984.5. [DOI] [PubMed] [Google Scholar]
  11. Küpfer A., Preisig R. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol. 1984;26(6):753–759. doi: 10.1007/BF00541938. [DOI] [PubMed] [Google Scholar]
  12. Meier U. T., Meyer U. A. Genetic polymorphism of human cytochrome P-450 (S)-mephenytoin 4-hydroxylase. Studies with human autoantibodies suggest a functionally altered cytochrome P-450 isozyme as cause of the genetic deficiency. Biochemistry. 1987 Dec 15;26(25):8466–8474. doi: 10.1021/bi00399a065. [DOI] [PubMed] [Google Scholar]
  13. Nakamura K., Goto F., Ray W. A., McAllister C. B., Jacqz E., Wilkinson G. R., Branch R. A. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther. 1985 Oct;38(4):402–408. doi: 10.1038/clpt.1985.194. [DOI] [PubMed] [Google Scholar]
  14. Vinks A., Inaba T., Otton S. V., Kalow W. Sparteine metabolism in Canadian Caucasians. Clin Pharmacol Ther. 1982 Jan;31(1):23–29. doi: 10.1038/clpt.1982.4. [DOI] [PubMed] [Google Scholar]
  15. Wedlund P. J., Aslanian W. S., McAllister C. B., Wilkinson G. R., Branch R. A. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther. 1984 Dec;36(6):773–780. doi: 10.1038/clpt.1984.256. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES